Anne Fulenwider, co-founder and co-CEO at Alloy Women’s Health, was at the JPMorgan Healthcare Conference in January when she heard something that stuck with her. Investors were talking openly about a "valley of death" for health startups that have outgrown seed funding but haven't yet hit the scale that justifies a mega-round.

Fulenwider's company, Alloy, a telehealth platform connecting women to menopause-trained physicians, sits squarely in that gap—and her response to the warning was essentially: We're not going there.

Alloy has raised $16 million in its most recent round, bringing its total to roughly $21 million . Midi Health, a direct competitor in the same menopause telehealth category, has raised more than $250 million and recently crossed a $1 billion valuation . Both companies are chasing the same underserved market. But only one of them thinks lean is better.

Same Crisis, Two Very Different Bank Accounts

The numbers behind the menopause opportunity are not in dispute. An estimated 1.3 million U.S. women enter menopause every year, and fewer than 2% receive what Alloy considers adequate treatment. The global menopause market was valued at roughly $17.8 billion in 2024 and is projected to grow steadily through 2030.

Midi Health's investors have framed the opportunity in similarly stark terms—citing a $26.6 billion annual economic toll from menopause-related workplace attrition and lost productivity as part of the rationale for its $100 million Series D. That round helped push Midi toward unicorn status within months.

Alloy, meanwhile, has spent the past several years quietly building toward something that sounds almost old-fashioned by comparison: a business that pays for itself.

Why The Gap Got This Wide

Dr. Sharon Malone, Alloy's chief medical advisor and a board-certified OB-GYN with nearly 30 years of practice, has watched this gap form from the exam room rather than the boardroom. After the 2002 Women's Health Initiative study reported that hormone therapy increased the risk of breast cancer, heart attack, and stroke, she says, "women abandoned hormone therapy in droves, even women who had been taking it for years without problems.

Malone estimates the scale of that fallout in plain numbers: assuming roughly 5,000 women enter menopause every day, she puts the toll at "more than 30 million women who either chose to forego treatment or were never offered hormone therapy" in the years since. The FDA's black box warning on hormone therapy was removed only recently. Malone calls the two decades in between a period "dominated by fear, not by science backed data.

Profitable, Then They Walked Away From It

Here's the detail that doesn't fit the usual startup narrative. Alloy reached profitability around the time of its Series A in November 2024—and then chose to reinvest that cushion back into growth rather than bank it. The company describes this as a deliberate trade-off, not a setback.

Monica Molenaar, Alloy's co-founder and co-CEO, frames it as a philosophy rather than a financial necessity. "It's always been really important to us to build a business responsibly," she explains. "We just need to always have the agency to not rely on anyone for anything. Frankly, women learn that, right?"

Colleen Foster, general partner at Amboy Street Ventures and an Alloy investor, observes that this kind of discipline is not incidental to women's health startups—it's structural. Women's health companies, she notes, have "demonstrated strong customer demand, attractive unit economics, and capital efficiency," yet typically need "significantly more traction than companies in established healthcare sectors before accessing institutional growth capital."

That mismatch, she contends, has produced "a generation of exceptionally disciplined founders who have learned to build meaningful businesses with far less capital than their peers." Alloy, in her view, is "a perfect example of this dynamic."

Foster points to an encouraging shift underway: Growth-stage investors are taking notice. At Amboy Street, she says, the firm is seeing "increasing participation from specialist healthcare investors, crossover funds, strategic acquirers, family offices, foundations, and institutional capital" that are pursuing exposure to what she calls one of healthcare's largest underserved markets.

Fulenwider spent nearly a decade as editor-in-chief of Marie Claire before co-founding Alloy, and she brings that media lens to how she talks about fundraising. In her view, the press loves a giant raise because it makes for a clean headline. But a giant raise also means a company has handed over control to a much larger group of stakeholders, each with their own timeline and expectations. Staying lean, in her telling, isn't a constraint Alloy is working around. That's the point.

The Math That Makes Lean Possible

That math only works because of how Alloy operates underneath the hood. The company says it has near-zero physician attrition and zero recruiting costs. Doctors come to Alloy on their own, often as a way to step back from traditional OB/GYN practice without giving up clinical work entirely. Alloy runs a dedicated community for its physicians and holds annual in-person training sessions, which the company points to as evidence of a culture that doesn't require venture-scale spending to retain talent.

Compare that to the typical playbook for a well-funded health startup: aggressive hiring, national marketing pushes, rapid geographic expansion. Midi Health, for context, now operates a clinician network spanning roughly 500 providers across all 50 states .

Alloy is making a bet that retention and word-of-mouth can substitute for that kind of capital-intensive growth, at least for now.

The Quiet Shift In How Women's Health Gets Pitched

There's a second thread running through all of this, and it's less about dollar amounts than about language. Fulenwider says an investor—someone who doesn't back Alloy but has backed a number of women-led companies—told her recently that she's had to pull back from highlighting "female founder" as a selling point when pitching to limited partners. The framing, Fulenwider was told, has become a liability in some rooms rather than an asset.

Malone is less interested in relitigating the science than in naming who let the fear persist. "I do, however, take issue with the regulators at NIH, academics and physicians who should have known better and who did little to push back in real time," she says, noting that countervailing interpretations of the WHI data existed as early as 2002 but were "drowned out by the 'experts' at NIH." Her summary of the two decades since: "you get indicted on page 1 and acquitted on C-17."

That shift is happening at the exact moment the underlying business case for women's health has arguably never been stronger. Midi's investors aren't talking about gender when they justify a $100 million investment round. They're talking about a $26.6 billion economic impact and a path to a billion-dollar valuation.

This raises an uncomfortable question: If the category is finally being taken seriously on pure financial terms, does it matter that some investors are simultaneously distancing themselves from the framing that helped get it here?

Two Theories Of How This Market Matures

Strip away the personalities and what's left is a genuine experiment playing out in real time. Midi is betting that capital and scale—insurance contracts, a 500-provider network, an AI-powered search tool for women's health information—will define who wins the menopause category. Alloy is betting that discipline, retention, and independence will matter more once the initial wave of investment enthusiasm cools.

Neither company is wrong, because neither bet has fully played out. But the gap between $21 million and $250 million isn't just a funding statistic. It's a preview of two very different versions of what menopause care looks like at scale. Which one other founders choose to copy may shape this market more than any single product launch.